PB2349: A PHASE 1, OPEN‐LABEL, MULTICENTER, DOSE‐ESCALATION STUDY OF SGR‐1505 AS MONOTHERAPY IN SUBJECTS WITH MATURE B‐CELL MALIGNANCIES.

Autor: Olszewski, Adam, Kahn, David, Yoo, Brian, Nie, Zhe, Krilov, Goran, Tan, Joanne, Wright, Hamish, Weiss, Daniel, Yin, Wu, Akinsanya, Karen
Zdroj: HemaSphere; 2023 Supplement 3, Vol. 7, p1-2, 2p
Databáze: Complementary Index
Externí odkaz: